 |
|
Efficacy of a Nicotine Lozenge for Smoking Cessation
Saul Shiffman, PhD;
Carolyn M. Dresler, MD;
Peter Hajek, PhD;
Simon J. A. Gilburt, PhD;
Darren A. Targett, MSc;
Kenneth R. Strahs, PhD
Arch Intern Med. 2002;162:1267-1276.
Background Since nicotine gum was introduced in the 1980s, nicotine replacement
therapy has become the most widely used pharmacological smoking cessation
treatment. Some smokers prefer acute oral forms, but many smokers reject chewing
gum. We tested the safety and efficacy of a new nicotine polacrilex lozenge
for smoking cessation.
Methods Double-blind, placebo-controlled, randomized clinical trial with parallel
arms testing 2- and 4-mg nicotine lozenges. Smokers (n = 1818) were assigned
to a lozenge dose on the basis of nicotine dependence, assessed by time to
the first cigarette of the day. Low-dependence smokers were randomized to
receive the 2-mg nicotine (n = 459) or placebo (n = 458) lozenge; high-dependence
smokers, the 4-mg nicotine (n = 450) or placebo (n = 451) lozenge. We assessed
abstinence at 6, 12, 24, and 52 weeks and analyzed craving and withdrawal
symptoms.
Results Treatment with the nicotine lozenge resulted in significantly greater
28-day abstinence at 6 weeks, for the 2-mg (46.0% vs 29.7%; odds ratio [OR],
2.10; 95% confidence interval [CI], 1.59-2.79; P<.001)
and the 4-mg (48.7% vs 20.8%; OR, 3.69; 95% CI, 2.74-4.96; P<.001) lozenges, compared with placebo. Significant treatment effects
were maintained for a full year. Smokers who used more lozenges achieved significantly
better treatment effects. Use of the active lozenge also resulted in reduced
craving and withdrawal. Most adverse events were moderate and resembled those
seen with nicotine gum.
Conclusion The nicotine lozenge is a safe and effective new treatment for smoking
cessation in low- and high-dependence smokers.
From Pinney Associates and the Departments of Psychology, Psychiatry,
and Pharmaceutical Science, University of Pittsburgh, Pittsburgh, Pa (Dr Shiffman);
GlaxoSmithKline Consumer Healthcare, Parsippany, NJ (Drs Dresler and Strahs),
and Weybridge, England (Dr Gilburt and Mr Targett); and the Department of
Psychology, University of London, London, England (Dr Hajek). Dr Shiffman
provides consulting to GlaxoSmithKline Healthcare on matters relating to smoking
control, and was compensated for his work on this project. Dr Shiffman also
has an interest in a novel nicotine replacement product that is not addressed
by this article. Dr Hajek has provided consulting to and received research
funding from pharmaceutical companies, including GlaxoSmithKline Consumer
Healthcare and Pharmacia Consumer Healthcare, Peapack, NJ. Drs Dresler, Gilburt,
and Strahs and Mr Targett are employed by GlaxoSmithKline Consumer Healthcare.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2002;162(11):1315-1316.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Adverse effects with use of nicotine replacement therapy among quitline clients
Ossip et al.
Nicotine Tob Res 2009;11:408-417.
ABSTRACT
| FULL TEXT
The missing link in tobacco control
Ebbert and Hays
CMAJ 2008;179:123-124.
FULL TEXT
State of the Art Reviews: Smoking Cessation: A Review of Treatment Considerations
Sullivan et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2007;1:201-213.
ABSTRACT
Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy
Tonnesen et al.
Eur Respir J 2007;29:390-417.
ABSTRACT
| FULL TEXT
Nicotine Replacement Therapy for Tobacco Use Cessation: Reference Table
Chu
Journal of Pharmacy Practice 2006;19:297-300.
ABSTRACT
Smoking and Diabetes: Helping Patients Quit
Ford and Shilliday
Clin. Diabetes 2006;24:133-137.
FULL TEXT
Characteristics of selectors of nicotine replacement therapy
Shiffman et al.
Tobacco Control 2005;14:346-355.
ABSTRACT
| FULL TEXT
Pharmacotherapy for Nicotine Dependence
Henningfield et al.
CA Cancer J Clin 2005;55:281-299.
ABSTRACT
| FULL TEXT
Treating Tobacco Dependence: State of the Science and New Directions
Lerman et al.
JCO 2005;23:311-323.
ABSTRACT
| FULL TEXT
Treatment of Tobacco Use in an Inpatient Psychiatric Setting
Prochaska et al.
Psychiatr. Serv. 2004;55:1265-1270.
ABSTRACT
| FULL TEXT
Nicotine replacement therapy in smoking cessation
Campbell
Thorax 2003;58:464-465.
FULL TEXT
OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02)
Evid. Based Nurs. 2003;6:e1-1.
FULL TEXT
Nicotine Lozenge Trial: A "Real-World" Perspective
Walsh and Shiffman
Arch Intern Med 2002;162:2632-2633.
FULL TEXT
Nicotine Lozenges and Smoking Cessation
JWatch Psychiatry 2002;2002:13-13.
FULL TEXT
Nicotine Lozenges and Smoking Cessation
Journal Watch Cardiology 2002;2002:3-3.
FULL TEXT
Nicotine Lozenges and Smoking Cessation
JWatch General 2002;2002:4-4.
FULL TEXT
|
